Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Status:
Completed

Trial end date:
2021-03-24

Target enrollment:

Participant gender:

This study is being conducted to provide a direct comparison of the efficacy, safety and tolerability for pazopanib and sunitinib (SUTENT)

Phase 3

Novartis Pharmaceuticals

Sunitinib